Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Heart Failure 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 283Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 229Nivolumab 183Cisplatin 174Biopsy 165Carboplatin 155Radiosurgery 142fludarabine 130Blood Specimen Collection 130Gemcitabine 120Surveys and Questionnaires 117Paclitaxel 115venetoclax 112Standard of Care 112Dexamethasone 105Bevacizumab 96Radiation 95Rituximab 91Oxaliplatin 89Cytarabine 88Capecitabine 86Drug Therapy 85Ipilimumab 83Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × empagliflozin × 90 days × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡